Accuracy of intraocular lens power calculation formulae in short eyes: A systematic review and meta-analysis

Ankur K Shrivastava, Swatishree Nayak, Ashish Mahobia¹, Mary Anto, Pranay Pandey

This review article attempts to evaluate the accuracy of intraocular lens power calculation formulae in short eyes. A thorough literature search of PubMed, Embase, Cochrane Library, Science Direct, Scopus, and Web of Science databases was conducted for articles published over the past 21 years, up to July 2021. The mean absolute error was compared by using weighted mean difference, whereas odds ratio was used for comparing the percentage of eyes with prediction error within ± 0.50 diopter (D) and ± 1.0 D of target refraction. Statistical heterogeneity among studies was analyzed by using Chi-square test and l² test. Fifteen studies including 2,395 eyes and 11 formulae (Barrett Universal II, Full Monte method, Haigis, Hill-RBF, Hoffer Q, Holladay 1, Holladay 2, Olsen, Super formula, SRK/T, and T2) were included. Although the mean absolute error (MAE) of Barrett Universal II was found to be the lowest, there was no statistically significant difference in any of the comparisons. The median absolute error (MedAE) of Barrett Universal II was the lowest (0.260). Holladay 1 and Hill-RBF had the highest percentage of eyes within ±0.50 D and ±1.0 D of target refraction, respectively. Yet their comparison with the rest of the formulae did not yield statistically significant results. Thus, to conclude, in the present meta-analysis, although lowest MAE and MedAE were found for Barrett Universal II and the highest percentage of eyes within ±0.50 D and ±1.0 D of target refraction was found for Holladay 1 and Hill-RBF, respectively, none of the formulae was found to be statistically superior over the other in eyes with short axial length.



Key words: Cataract, intraocular lens, mean absolute error, median absolute error, power calculation formulae, short eyes

Cataract surgery remains one of the most commonly performed ophthalmological procedures worldwide owing to the aging population and increasing life expectancy.^[1,2] Even in a meticulously performed surgery, the actual visual outcome can match the expected visual outcome by accurate biometry.

The advent of optical biometry circumvented the operator-induced bias encountered in ultrasound biometry. Soon partial coherence interferometry (PCI) became the gold standard optical biometer owing to its precision in measurements along with ease of use in clinical settings.^[3]Optical low coherence reflectometry (OLCR) and swept-source optical coherence tomography biometers were its successors, which although maintained the same precision of measurements, provided additive information on several parameters such as lens thickness, central corneal thickness, anterior chamber depth (ACD), horizontal white-to-white diameter, and corneal radii.^[4] The incorporation of these parameters into the intraocular lens (IOL) power calculation formulae gave a better prediction of the effective lens position.

However, among the wide range of available formulae, none is completely accurate in all scenarios. Modern formulae show comparable refractive outcomes in eyes with normal

Received: 20-Apr-2021 Accepted: 06-Sep-2021 Revision: 17-Aug-2021 Published: 25-Feb-2022 axial length (AL).^[5] But when we deal specifically with short eyes (AL <22 mm), they gave variable results. Hence, the deliberation for choosing the most accurate formula, so as to obtain an optimal postoperative visual outcome in the subgroup of short eyes continues. In 2018, a meta-analysis on short eyes had already been carried out by Wang *et al.*^[6] With set down of protocols for conducting a study on IOL power accuracy, it was recommended to compare median absolute error (MedAE) rather than mean absolute error (MAE) and also includes the percentage of eyes with prediction error (PE) within ±0.25, ±0.50, and ±1.0 diopter (D) of target refraction.^[7,8] Hence, the present meta-analysis was carried out taking into account these recommendations.

Methods

We carried out this meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.^[9] Ethics committee approval was not required as our review relied entirely on publicly available data that are already published. Nonetheless, the study methods adhered to the tenets of the Declaration of Helsinki.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

Cite this article as: Shrivastava AK, Nayak S, Mahobia A, Anto M, Pandey P. Accuracy of intraocular lens power calculation formulae in short eyes: A systematic review and meta-analysis. Indian J Ophthalmol 2022;70:740-8.

© 2022 Indian Journal of Ophthalmology | Published by Wolters Kluwer - Medknow

Department of Ophthalmology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, ¹SaiBaba Eye Hospital, Raipur, Chhattisgarh, India

Correspondence to: Dr. Ankur K Shrivastava, Flat No 603, Type 5A, AIIMS Residential Complex, Kabir Nagar, Raipur, Chhattisgarh - 492099, India. E-mail: shrivastavadrankur@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Search methods

Two authors independently searched PubMed, Embase, Cochrane Library, Science Direct, Scopus, and Web of Science databases for research articles published over the past 21 years, up to July 2021. Search terms used for PubMed were short eyes* OR short axial length* AND Phacoemulsification AND Calculat* OR Formula* AND IOL. The title and abstract of the retrieved literature were then screened. The selected articles were further filtered by reading the full text and assessed for eligibility. Articles cited in the reference list of these eligible articles were also screened manually.

Inclusion and exclusion criteria

The studies included in the meta-analysis met the following inclusion criteria: (1) population: (a) patients older than 18 years of age, (b) eyes with AL less than 22 mm; (2) intervention: (a) biometry done by optical method, (b) eyes that underwent uneventful phacoemulsification surgery; (3) comparison: at least two of the following IOL power calculation formulae used – Barrett Universal II, Haigis, Hill-RBF, Hoffer Q, Holladay 1, Holladay 2, and SRK/T; (4) outcome: studies that reported at least one of the three outcome measures – MAE, MedAE, or percentage of eyes with PE within ±0.50 and ±1.0 D of target refraction; (5) study design: Prospective and retrospective.

The exclusion criteria were as follows: (1) history of corneal refractive surgery; (2) any ocular pathology affecting refraction; (3) toric, multifocal, piggyback IOL, or IOLs not implanted in the bag; (4) older generation formulae such as Binkhorst II, SRK I, or SRK II used; (5) review articles, studies under trial, editorials, conference abstracts, previous meta-analysis, discussion papers, full text not available in English, or animal studies.

Data extraction

Two authors extracted data regarding study design, methodology, participant demographics, and baseline characteristics from all included studies independently and matched their results. Any discrepancy found was resolved by discussion and confirmation with the third author. If standard deviation (SD) data could not be extracted from full-text articles or even after contacting the authors, we used the mean SD of the remaining studies.

Quality assessment

The study quality was assessed by using a modified checklist adapted from the Quality Assessment of Diagnostic Accuracy Studies–2 (QUADAS-2) tool.^[10] The evaluation of bias was divided into four domains: patient selection, index test, reference standard, and last, flow and timing of patients. Applicability concerns were assessed using three domains: patient selection, index test, and reference standard. Each domain could have a high risk, low risk, or unclear risk of bias.

Statistical analysis

Data were analyzed for MAE, MedAE, and percentage of eyes with PE within ± 0.50 and ± 1.0 D of target refraction. We analyzed the relative effect size of continuous outcomes like MAE using weighted mean difference (WMD) with 95% confidence interval (CI). The relative effect size of the percentage of eyes with PE within ± 0.50 and ± 1.0 D of target refraction, which was a binary outcome, was calculated as odds ratio (OR) with a 95% CI. Statistical methods utilized were inverse variance for continuous data and Mantel–Haenszel for dichotomous data. A *P* value less

than 0.05 was considered statistically significant in both. Statistical heterogeneity among studies was analyzed by using Chi-square test and *I*² test. When the *I*² value was more than 50% and *P* value was less than 0.1, random-effect model was used for analysis; otherwise a fixed-effect model was used. Sensitivity analysis was conducted to identify sources of significant heterogeneity. Te funnel plot was used to assess publication bias. Only descriptive analysis was performed for MedAE as it is not suitable for meta-analysis. Statistical analysis was carried out using Review Manager software (RevMan, Version 5.4).^[11]

Results

Literature selection results

The detailed process of literature search and study selection is depicted in Fig. 1. Initially, 2,094 studies were identified through a database search. After the removal of 48 duplicate studies, 2,046 eligible titles were identified and screened by review of the abstract. Of these, 28 full-text articles were retrieved. After excluding 13 studies based on predefined inclusion criteria, 15 studies were included in this meta-analysis.

Study characteristics

The characteristics of eligible studies are summarized in Table 1. A total of 2,395 eyes with AL in the range of 18.77 to 21.99 mm were included in the analysis. The sample size ranged from 15 to 608 eyes. Formulae included were Barrett Universal II, Haigis, Hill-RBF, Hoffer Q, Holladay 1, Holladay 2, and SRK/T. A few studies also used newer generation formulae such as the Full Monte method, Kane, Ladas Super formula, Olsen, and T2.

Quality of included studies

A modified checklist adapted from QUADAS-2 tool was employed to assess the study quality [Fig. 2]. Detailed assessment questionnaire and its results are provided [Additional File 1]. Ten of the 15 studies did not report whether the patient selection was consecutive or random and hence had an unclear risk of bias. On analyzing the reference standard used, 10 studies had a high risk of bias due to the use of subjective refraction for calculating postoperative spherical equivalent (SE). Most of the studies were of high quality as far as index tests, the inclusion of patients, the flow of patients, and applicability were concerned.

Outcomes

The outcome variables included in our analysis were MAE, MedAE, and the percentage of eyes with PE within ±0.50 and ±1.0 D of target refraction. This meta-analysis included 2,395 eyes, of which 1,302 eyes were analyzed for Barrett Universal II, 1,543 eyes for Haigis, 1,105 eyes for Hill-RBF, 2,192 eyes for Hoffer Q, 2,129 eyes for Holladay 1, 1,272 eyes for Holladay 2, and 2,016 eyes for SRK/T formulae.

Mean absolute error

The MAE and standard error of all the formulae included in the analysis showed the lowest value for Barrett Universal II [Fig. 3(I)]. It performed equally well as Haigis, Hoffer Q, and SRK/T with WMD and 95% CI of -0.00 (-0.04, 0.03) for the three pairs [Fig. 3IIA, B, and C]. The WMD and 95% CI of Barrett Universal II with Hill-RBF, Holladay 1, and Holladay 2 were 0.02 (-0.01, 0.06); 0.02 (-0.01, 0.06), and 0.03 (-0.01, 0.06), respectively [Fig. 3II D, E, and F]. Although the MAE of Barrett Universal II was found to be the lowest, there was no statistically significant difference in any of the comparisons.



Figure 1: Flow chart of article selection. Abbreviations: FLACS = Femtosecond laser-assisted cataract surgery; IOL=Intraocular lens



Figure 2: Quality assessment of the included studies based on modified QUADAS-2 tool. Abbreviations: QUADAS-2 = Quality Assessment of Diagnostic Accuracy Studies-2

Median absolute error

Table 2 shows the descriptive analysis of MedAE of all the formulae included in the analysis. Nine of the 15 studies have reported this

parameter. The MedAE of Barrett Universal II was the lowest (0.260) followed by Hill-RBF (0.300), Holladay 1 (0.302), Haigis (0.308), Holladay 2 (0.320), SRK/T (0.327), and Hoffer Q (0.340).

| Table 1: Charact | eristics of s | tudy participants | | | | | | | |
|---|--|--|---|-------------------------|--|--|---|--|--|
| Study | Year | Country | Study design | | Number of eyes | Age (years±SD) | Axial length, mm±SD (Range) | Method of calculating RPE | Lens Constant Used |
| Aristodemou <i>et al.</i> [[] | 15] 2011 | United Kingdom | Retrospective | | 608 | NA | 21.57 (20.00-21.99) | Postop SE-PR | Optimized constants |
| Cooke and Cooke ^{[;} | 23] 2016 | NSA | Retrospective | | 41 | NA | 21.69 (20.84-22.00) | Postop SE-PR | Optimized constants |
| Darcy <i>et al.</i> ^[25] | 2020 | Я | Retrospective | | 766 | AN | ≤ 22 | Postop SE-PR | Optimized constants For Haigis a0- optimized, a1, a2- ULIB |
| Day <i>et al.</i> [17] | 2012 | NΚ | Retrospective | | 163 | 57±10 | 21.2±0.60 (19.23-21.98) | Postop SE-PR | Optimized constants |
| Eom <i>et al.</i> ^[18] | 2014 | South Korea | Retrospective cross | -sectional | 75 | 70.1±6.8 | 21.69±0.29 (20.32-21.99) | Postop SE-PR | Optimized constants |
| Gavin and Hammo | nd ^[16] 2008 | UK | Retrospectively Pro: | spective | 41 | NA | 21.51 (20.29-21.96) | PR-Postop SE | Manufacturer's constants |
| Gökce <i>et al.</i> ^[19] | 2017 | NSA | Retrospective case. | series | 86 | 72±8 | 21.53±0.56 (18.80-22.00) | Postop SE-PR | Optimized constants |
| Kane <i>et al.</i> ^[5] | 2016 | Australia | Retrospective case. | series | 156 | NA | ≤22 | Postop SE-PR | Optimized constants |
| Kane <i>et al</i> . ^[26] | 2017 | Australia | Retrospective case | series | 137 | NA | ≤22 | Postop SE-PR | Optimized constants |
| Khatib <i>et al.</i> ^[21] | 2021 | India | Retrospective obser | vational | 66 | NA | | Postop SE-PR | Optimized constants |
| Shrivastava <i>et al.</i> ^{[2(} | ^{0]} 2018 | India | Retrospective obser | vational | 50 | 58.54±10.36 | 21.61±0.27 (20.76-21.96) | Postop SE-PR | Optimized constants |
| Srivannaboon <i>et a</i> | ([22] 2013 | Thailand | Prospective compar | ative. | 15 | NA | 21.44 (18.77-21.94) | Postop SE-PR | ULIB constants |
| Terzi <i>et al</i> . ^[27] | 2009 | Germany | Retrospective | | 19 | 53±7 | 21.24±0.55 (20.13-21.97) | PR-Postop SE | Optimized constants |
| Wang <i>et al.</i> ^[6] | 2013 | China | Retrospective | | 33 | NA | 21.52±0.47 | Postop SE-PR | Optimized constants |
| Zhao <i>et al</i> . ^[13] | 2018 | China | Retrospective | | 139 | NA | <21 | PR-Postop SE | ULIB constants |
| Study | Version of bio | ometer N | Method of K Fol neasurement | dn-woll | Refraction | | IOL implanted | Formulae | i used |
| Aristodemou <i>et al</i> . ^[15] | NA | - | OLMaster 1 | month | Subjective | | Sofport IOL and Ak Fit IOL | reos Hoffer Q, | Holladay 1, SRK/T |
| Cooke and Cooke ^[23] | Lenstar LS 90 3.02) and IOLI (Version 5.4) | 0 (Version C Master t F | Dptical 3 biometer (both T DLCR and T PCI) | weeks to 3 nonths | Subjective | | AcrysofSN60WF | Barrett Ur Q, Hollad Ref, Holla Olsenstar SRK-T, S | iiversal II, Haigis, Hoffer ay 1, Holladay 2No day 2Pre surg Ref, dalone, OlsenOLCR uper Formula, T2 |
| Darcy <i>et al.</i> | IOLMaster (Ca Meditec, AG) | arl Zeiss, l | OLMaster | AN | Subjective | | SA60AT, Superflex Aspheric920 H, C-Flex Aspheric970 AkreosAdaptAO | Barrett Ur Hoffer Q, C, Kane, Ols | iiversal II, Haigis, Hill-RBF, Holladay1, Holladay 2, en, SRK∕T |
| Day <i>et al.</i> ^[17] | IOLMaster (Ca Meditec, Inc, I USA) | arl Zeiss, I ^I Dublin, CA, | OLMaster 2 v | 2-17.7 veeks | Autorefractic series autore Rotterdam, | on (Topcon KR8 efractor) Topcol The Netherland | 3000 Akreos AO, Akreosn, Adapt, Corneal ACFls OculentisLentis L3C | Haigis, He ReD, 22-1 | offer Q, Holladay1, SRK/T |
| Eom <i>et al.</i> ^[18] | IOLMaster (Vé | ersion 5.02) II | OLMaster w | 3-10 veeks | Autorefracto (RK-F1; Can | r/Keratometer ion, Tokyo, Jap | Alcon Acrysof IQ an) | Haigis, Ho | offer Q |
| Gavin and Hammond ^[16] | IOLMaster (Ze systems) | eiss-Humphrey l | OLMaster 2-3 | 3 weeks | Autorefracto AR-2, Canoi | meter (Canon Դ, Tokyo) | AllerganMA60 | Hoffer Q, | SRK/T |
| | | | | | | | | | |

Contd...

| Table 1: Conte | d | | | | | |
|--|---|---|--------------------|---|---|---|
| Study | Version of biometer | Method of K measurement | Follow-up | Refraction | IOL implanted | Formulae used |
| Gökce <i>et al.</i> ^[19] | Lenstar LS900 (Version V 4.1.1, Haag Streit AG) | Lenstar | >3 weeks | Subjective | Alcon Acrysof SN60WF, SN6AT, SA60AT, Tecnis, ZCBOO, ZCT | Barrett Universal II, Haigis, Hill-RBF, Hoffer Q, Holladay 1, Holladay 2, and Olsen |
| Kane <i>et al.</i> ^[5] | IOLMaster (Version 5.4, Carl Zeiss, Meditec, AG) | IOLMaster | 2 weeks | Subjective | AcrysofIQSN60WF | Barrett Universal II, Haigis, Hoffer Q, Holladay1, Holladay 2, SRK/T, T2 |
| Kane <i>et al.</i> | IOLMaster (Version 5.4, Carl Zeiss, Meditec, AG) | IOLMaster | 2 weeks | Subjective | Acrysof IQ SN60WF | Barrett Universal II, Full Monte method, Hill- RBF, Holladay 1, Ladas Super formula |
| Khatib <i>et al.</i> ^[21] | Lenstar LS 900 | Lenstar | 2 weeks | Subjective | Acrysof IQ SN60WF, Tecnis ZCB00 | Barrett Universal II, EVO, Hill-RBF |
| Shrivastava <i>et al.</i> ^[20] | IOLMaster 500 (Version 5.4, Carl Zeiss, Meditec, AG) | IOLMaster | 1 month | Autorefractometer (Accuref K-900/R-800, Rexxam Co. Ltd.) | Acrysof SN6CWS | Barrett Universal II, Haigis, Hill- RBF, Hoffer Q, Holladay 2, SRK/T |
| Srivannaboon <i>et al</i> . ^[22] | IOLMaster (Carl Zeiss, Meditec, Jena, Germany) | IOLMaster | 3 months | Subjective | Hoya PY60AD | Haigis, Hoffer Q, Holladay 2 with LT, Holladay 2 without LT |
| Terzi <i>et al.</i> | IOLMaster (Carl Zeiss, Meditec, AG) | AL by PCI, Keratometry not clear | 1 month | Subjective | Acrysof SA60AT, Sensar AR40e | Haigis, Hoffer Q, Holladay 2, SRK/T |
| Wang <i>et al.</i> ^[6] | IOLMaster (Carl Zeiss, Jena, Germany) | IOLMaster | 3 months | Autorefractometer (Topcon AR, Tokvo, Japan) | Acrysof SA60AT | Haigis, Hoffer Q, Holladay 1, SRK/T |
| Zhao <i>et al.</i> ^[13] | Zeiss IOLMaster (Version 4.02) | AL- IOLMaster, Manual keratometry | 1-3 months | Subjective | AA4203 | Haigis, Hoffer Q, Holladay 1, Holladay 2, SRKT |
| Postop SE=postop | erative spherical equivalent; PR=predic | sted refraction; ULIB=Us | ser Group for Lase | sr Interference Biometry; AL=axial length; C | DLCR=optical low-coherence reflec | tometry; PCI=partial coherence interferometry |



Figure 3: (I) The overall MAE and standard error of all formulae included in analysis. (II) Forest plots showing comparison of MAE between Barrett Universal II and Haigis (A), Hoffer Q (B), SRK/T (C), Hill-RBF (D), Holladay 1 (E), and Holladay 2 (F). Abbreviations: MAE = Mean absolute error; D = Diopter; PE = Prediction error



Figure 4: (I) Percentage of eyes with prediction error within ± 0.50 D of target refraction of all the formulae included in the analysis. (II) Forest plots showing comparison between Holladay 1 and Barrett Universal II (A), Haigis (B), Hill-RBF (C), Hoffer Q (D), Holladay 2 (E), and SRK/T (F). Abbreviations: D = Diopter; PE = Prediction error

Table 2: Descriptive analysis of median absolute error of all the formulae included in the analysis

| Formula | Number of studies | Range |
|----------------------|-------------------|-------------|
| Barrett Universal II | 7 | 0.260-0.540 |
| Full Monte | 1 | 0.462 |
| Haigis | 11 | 0.308-0.570 |
| Hill-RBF | 5 | 0.300-0.520 |
| Hoffer Q | 13 | 0.340-0.580 |
| Holladay 1 | 9 | 0.302-0.630 |
| Holladay 2 | 8 | 0.320-0.560 |
| Olsen | 3 | 0.325-0.350 |
| Super formula | 2 | 0.320-0.370 |
| SRK/T | 10 | 0.327-0.690 |
| T2 | 2 | 0.341-0.415 |

Percentage of eyes with prediction error within ±0.50 D of target refraction

Fig. 4(I) shows the percentage of eyes with PE within ± 0.50 D of target refraction of all the formulae included in the analysis. Holladay 1 had the highest percentage of eyes. On analyzing the forest plots, OR and 95% CI of Holladay 1 as compared with Barrett Universal II, Haigis, Hill-RBF, Hoffer Q, Holladay 2, and SRK/T formulae were 0.91 (0.68,1.21), *P* value = 0.51, 0.95 (0.73, 1.25), *P* value = 0.73, 0.94 (0.63, 1.40), *P* value = 0.76, 0.85 (0.72, 1.02), *P* value = 0.08, 1.10 (0.77, 1.57), *P* value = 0.59, and 1.19 (0.99, 1.43), *P* value = 0.07, respectively, as shown in Fig. 4(II). None of the comparisons showed statistically significant results [Additional file 3].

Percentage of eyes with prediction error within ±1.0 D of target refraction

Hill-RBF had the highest value when the percentage of eyes with PE within ±1.0 D of target refraction was considered [Additional file 4 (I)]. On analyzing the forest plots none of the comparisons yielded statistically significant results [Additional file 4 (II)].

There was only one study that reported the percentage of eyes with PE within ±0.50 and ±1.0 D for comparison between Hill-RBF and SRK/T formulae, and hence forest plots were not made according to the Cochrane Collaboration guidelines.^[12]

Heterogeneity and *I*²

Additional file 2 (B, C, D, and E) shows both substantial as well as statistical heterogeneity on comparison of MAE of Haigis with Hoffer Q, Holladay 1, Holladay 2, and SRK/T. A random-effect model was chosen in these cases. On doing a sensitivity analysis [Additional file 5], it was observed that *I*² reduced to 0% in all the four comparisons by omitting the study by Zhao *et al.*^[13] The result was more in favor of Holladay 2, although not statistically significant when the above-mentioned study was excluded from the comparison between Haigis and Holladay 2. However, the results were not altered in the rest of the comparisons.

Publication bias

The funnel plot drawn for comparison between Haigis and Hoffer Q, which included 11 studies, showed that the study by Zhao *et al.*^[13] was outside the funnel [Additional file 6].

Discussion

MAE had long been reported as a parameter for comparing formula accuracy. As suggested by Hoffer *et al.*,^[7] absolute error does not follow normal Gaussian distribution; so reporting and comparing MedAE gives a better idea about formula accuracy. MedAE, by negating the effect of outliers, had an added advantage. The reporting percentage of eyes within ±0.50 and ±1.0 D of target refraction is also recommended as this parameter is most closely related to patient satisfaction after surgery. With this background present, meta-analysis was carried out by comparing all the recommended parameters, that is, MAE, MedAE, and percentage of eyes with PE within ±0.50 and ±1.0 D of target refraction, to find the best-performing formula in short AL eyes.

Studies conducted in various parts of the world have advocated different formulae for eyes with short AL. Hoffer Q, a preferred formula for short eyes, has been reported as the most accurate in the study done by Hoffer^[14]; although the study included only 10 short eyes and used ultrasound biometry. Also a study by Aristodemou *et al.*^[15] considered it to give the best refractive outcome in eyes shorter than 21.00 mm; while between 21.00 and 21.49 mm, it was found to be equally good as Holladay 1. It is worthwhile to mention here that MAE was the only parameter compared in this study. Gavin and Hammond^[16] considered Hoffer Q as an accurate formula in short eyes, but the comparison was done only against SRK/T. In a study by Day *et al.*,^[17] although Hoffer Q had the lowest MAE on using manufacturer's constants; all formulae performed equally well after lens constant optimization.

Contrary to this, Haigis has been described as the most accurate formula in short eyes by some authors. Zhao *et al.*^[13] found optimized Haigis formula more accurate than other formulae in eyes with AL less than 21 mm. A study done by Eom *et al.*^[18] found it to be more accurate as compared with Hoffer Q when ACD was less than 2.4 mm. The meta-analysis carried out by Wang *et al.*^[6] has also recommended Haigis as the formula of choice for short eyes. But a general consensus regarding the formula of choice in short eyes is still missing.

In the present analysis, although Barrett Universal II had the lowest MAE and MedAE, the results were not statistically significant when compared with the rest of the formulae. Holladay 1 and Hill-RBF had the highest percentage of eyes within ±0.50 and ±1.0 D of target refraction, respectively. Yet their comparison with the rest of the formulae also did not yield statistically significant results. Our results were in concordance with that of Kane *et al.*^[5] who found no statistical difference between the formulae analyzed, thus making it difficult to choose any one IOL power calculation formula over the other, in eyes with short AL. The study results of Gökce *et al.*,^[19] Shrivastava *et al.*,^[20] and Khatib *et al.*^[21] were in agreement with this.

Over a period of years, there have been continuous developments in the field of IOL power calculation. It is an established fact now that optimization of lens constant has to be mandatorily done for conducting any study on IOL calculation accuracy. In this analysis, Gavin and Hammond^[16] used the manufacturer's constant and found Hoffer Q better, whereas Srivannaboon *et al.*^[22] and Zhao *et al.*^[13] used User Group for Laser Interference Biometry constants. The results of Srivannaboon *et al.*^[22] showed no statistically significant difference between the formulae, whereas Zhao *et al.*^[13] found Haigis formula to be more appropriate. It is interesting to note that in studies using optimized constants, none of the formulae was found to be statistically superior over the other. Second, the method of calculating refractive prediction error (RPE) also influences the results. Although most studies have calculated RPE as

postoperative SE minus predicted refraction (PR), there are also a few, which have taken PR minus postoperative SE as RPE. Hence, this fact has to be considered before statistical analysis and comparing formula accuracy. Third, the difference in version and make of the optical biometers also affects the study results. This fact has been clearly established in the study by Cooke and Cooke^[23] who showed that, in the subgroup of short eyes, Barrett Universal II achieved the best results when PCI measurements were used, whereas Olsen outperformed other formulae on using OLCR values. The strength of the current meta-analysis is that we have contemplated on all the above-mentioned facts and hence put forth a complete picture by analyzing the recommended parameters of formula accuracy, that is, MAE, MedAE, and percentage of eyes with prediction errors within ±0.50 and ±1.0 D of target refraction rather than only MAE as done by Wang *et al.*^[6]

As an effort to minimize heterogeneity and reduce bias, our meta-analysis excluded studies where optical biometry was not used. The random-effect model was used in cases with substantial as well as statistical heterogeneity. Sensitivity analysis showed that I^2 reduced to 0% in all the four pairs of comparison (Haigis with Hoffer Q, Holladay 1, Holladay 2, and SRK/T) by omitting the study of Zhao et al.^[13] On analyzing, we found that in a study by Zhao et al., [13] although AL measurement was done by IOLMaster; keratometry was done manually. The subgroup analysis of the keratometry method showed that the difference is statistically significant (P = 0.03), which was accounted for the source of heterogeneity. It is also a well-known fact that racial differences can affect the accuracy of IOL calculations.^[24] The studies included in this meta-analysis are from various regions of the world, thus making our results more generalized rather than pertaining to a particular subcontinent.

Conclusion

Thus, to conclude, in the present meta-analysis, although lowest MAE and MedAE were found for Barrett Universal II and highest percentage of eyes within ± 0.50 D and ± 1.0 D of target refraction was found for Holladay 1 and Hill-RBF, respectively, none of the formulae was found to be statistically superior over the other in eyes with short AL.

Availability of data and materials

All data analyzed in this study are included in the article and its additional files.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

- Busbee BG, Brown MM, Brown GC, Sharma S. Incremental cost-effectiveness of initial cataract surgery. Ophthalmology 2002;109:606–12.
- Lundstrom M, Wendel E. Duration of self-assessed benefit of cataract extraction: A long term study. Br J Ophthalmol 2005;89:1017–20.
- Kaswin G, Rousseau A, Mgarrech M, Barreau E, Labetoulle M. Biometry and intraocular lens power calculation results with a new optical biometry device: Comparison with the gold standard. J Cataract Refract Surg 2014;40:593-600.
- Kunert KS, Peter M, Blum M, Haigis W, Sekundo W, Schutze J, et al. Repeatability and agreement in optical biometry of a new swept-source optical coherence tomography–based biometer versus partial coherence interferometry and optical low-coherence reflectometry. J Cataract Refract Surg 2016;42:76-83.
- 5. Kane JX, Van Heerden A, Atik A, Petsoglou C. Intraocular lens power formula accuracy: Comparison of 7 formulas. J Cataract

Refract Surg 2016;42:1490-500.

- 6. Wang Q, Jiang W, Lin T, Wu X, Lin H, Chen W. Meta-analysis of accuracy of intraocular lens power calculation formulas in short eyes. Clin Exp Ophthalmol 2018;46:356-63.
- Hoffer KJ, Aramberri J, Haigis W, Olsen T, Savini G, Shammas HJ, et al. Protocols for studies of intraocular lens formula accuracy. Am J Ophthalmol 2015;160:403-5.e1.
- Wang L, Koch DD, Hill W, Abulafia A. Pursuing perfection in intraocular lens calculations: III. Criteria for analyzing outcomes. J Cataract Refract Surg 2017;43:999-1002.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, *et al.* The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009;339:b2700. doi: https://doi.org/10.1136/bmj .b2700.
- Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, *et al.* QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36.
- 11. Review Manager (RevMan) [Computer program]. Version 5.4, The Cochrane Collaboration, 2020.
- 12. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
- Zhao Y, Wang Z, Zhao S, Wang K, Zhu S. Which IOL formula should be used to determine the lens power estimation? A data analysis based on 3258 eyes. Int J Clin Exp Med 2018;11:8646-50.
- 14. Hoffer KJ. Clinical results using the Holladay 2 intraocular lens power formula. J Cataract Refract Surg 2000;26:1233-7.
- Aristodemou P, Knox Cartwright NE, Sparrow JM, Johnston RL. Formula choice: Hoffer Q, Holladay 1, or SRK/T and refractive outcomes in 8108 eyes after cataract surgery with biometry by partial coherence interferometry. J Cataract Refract Surg 2011;37:63-71.
- 16. Gavin EA, Hammond CJ. Intraocular lens power calculation in short eyes. Eye 2008;22:935-8.
- 17. Day AC, Foster PJ, Stevens JD. Accuracy of intraocular lens power calculations in eyes with axial length<22.00 mm. Clin Exp Ophthalmol 2012;40:855-62.
- Eom Y, Kang SY, Song JS, Kim YY, Kim HM. Comparison of Hoffer Q and Haigis formulae for intraocular lens power calculation according to the anterior chamber depth in short eyes. Am J Ophthalmol 2014;157:818-24.
- Gökce SE, Zeiter JH, Weikert MP, Koch DD, Hill W, Wang L. Intraocular lens power calculations in short eyes using 7 formulas. J Cataract Refract Surg 2017;43:892-7.
 Shrivastava AK, Behera P, Kumar B, Nanda S. Precision of
- Shrivastava AK, Behera P, Kumar B, Nanda S. Precision of intraocular lens power prediction in eyes shorter than 22 mm: An analysis of 6 formulas. J Cataract Refract Surg 2018;44:1317-20.
- Khatib ZI, Haldipurkar SS, Shetty V, Dahake H, Nagvekar P, Kashelkar P. Comparison of three newer generation freely available intraocular lens power calculation formulae across all axial lengths. Indian J Ophthalmol 2021;69:580-4.
- 22. Srivannaboon S, Chirapapaisan C, Chirapapaisan N, Lertsuwanroj B, Chongchareon M. Accuracy of Holladay 2 formula using IOLMaster parameters in the absence of lens thickness value. Graefes Arch Clin Exp Ophthalmol 2013;251:2563-7.
- 23. Cooke DL, Cooke TL. Comparison of 9 intraocular lens power calculation formulas. J Cataract Refract Surg 2016;42:1157-64.
- Savini G, Negishi K, Hoffer KJ, Lomoriello DS. Refractive outcomes of intraocular lens power calculation using different corneal power measurements with a new optical biometer. J Cataract Refract Surg 2018;44:701-8.
- Darcy K, Gunn D, Tavassoli S, Sparrow J, Kane JX. Assessment of the accuracy of new and updated intraocular lens power calculation formulas in 10 930 eyes from the UK National Health Service. J Cataract Refract Surg 2020;46:2-7.
- Kane JX, Van Heerden A, Atik A, Petsoglou C. Accuracy of 3 new methods for intraocular lens power selection. J Cataract Refract Surg 2017;43:333-9.
- Terzi E, Wang L, Kohnen T. Accuracy of modern intraocular lens power calculation formulas in refractive lens exchange for high myopia and high hyperopia. J Cataract Refract Surg 2009;35:1181-9.

Modified check-list adapted from the QUADAS-2 tool

Assessment of risk of bias

Domain 1: Patient selection

Question 1: Was a consecutive or random sample of patients enrolled?

- 'yes' \rightarrow low risk of bias
- 'unclear' \rightarrow unclear risk of bias
- 'no' \rightarrow high risk of bias.

Question 2: Did the study avoid inappropriate exclusions?

- 'no' for < 10% of patients or 'yes' \rightarrow low risk of bias
- 'unclear' \rightarrow unclear risk of bias
- 'no' for $\geq 10\%$ of patients \rightarrow high risk of bias.

Domain 2: Index test

Were the index test result read without knowing the result of the reference standard?

- 'yes' \rightarrow low risk of bias
- 'unclear' \rightarrow unclear risk of bias
- 'no' \rightarrow high risk of bias

Domain 3: Reference standard

Could the calculation of refractive prediction error have introduced bias?

- Objective Refraction \rightarrow low risk of bias
- 'unclear' \rightarrow unclear risk of bias
- Subjective refraction \rightarrow high risk of bias

Domain 4: Flow and timing

Question 1: Did all patients receive the same reference standard?

- 'no' but for < 10% of patients or 'yes' \rightarrow low risk of bias
- 'unclear' \rightarrow unclear risk of bias
- 'no' for $\geq 10\%$ of patients \rightarrow high risk of bias.

Question 2: Was there an appropriate interval between the index test and reference standard?

- post-operative refraction done two weeks or later after surgery → low risk of bias
- 'unclear' \rightarrow unclear risk of bias
- post-operative refraction done within two weeks of surgery \rightarrow high risk of bias.

Assessment of applicability concerns

Domain 1: Patient selection

Is there concern that included patients do not match review question?

- 'no' \rightarrow low risk of bias
- 'unclear' \rightarrow unclear risk of bias
- 'yes' \rightarrow high risk of bias

Domain 2: Index test

Is there concern that index test, its conduct or interpretation differ from review question?

- 'no' \rightarrow low risk of bias
- 'unclear' \rightarrow unclear risk of bias
- 'yes' \rightarrow high risk of bias.

Domain 3: Reference standard

Is there concern that target condition as defined by the reference standard does not match the review question?

- 'no' \rightarrow low risk of bias
- 'unclear' \rightarrow unclear risk of bias
- 'yes' \rightarrow high risk of bias.

Quality assessment of the included studies based on modified QUADAS- 2 tool

| Study | | R | sk of bias | | Ар | plicability con | cerns |
|----------------------|-------------------|---------------|--------------------|-----------------|-------------------|-----------------|-----------------------|
| | Patient selection | Index test | Reference standard | Flow and timing | Patient selection | Index test | Reference standard |
| Aristodemou 2011 | © | ٢ | 8 | © | © | ٢ | ٢ |
| Cooke 2016 | ٢ | ٢ | 8 | ٢ | ٢ | ٢ | ٢ |
| Darcy 2020 | ٢ | ٢ | 8 | ? | ? | ٢ | ٢ |
| Day 2012 | ٢ | ٢ | ٢ | ٢ | ٢ | ٢ | ٢ |
| Eom 2014 | ? | ٢ | ٢ | ٢ | ٢ | ٢ | ٢ |
| Gokce 2017 | ? | ٢ | 8 | ٢ | ٢ | ٢ | ٢ |
| Gavin 2008 | ? | ٢ | ٢ | ٢ | ٢ | ٢ | ٢ |
| Kane 2016 | ? | ٢ | 8 | © | © | ٢ | ٢ |
| Kane 2017 | ? | ٢ | 8 | © | © | ٢ | ٢ |
| Khatib 2021 | ? | ٢ | 8 | © | © | ٢ | ٢ |
| Shrivastava 2018 | ? | ٢ | ٢ | ٢ | ٢ | ٢ | ٢ |
| Srivannaboon 2013 | © | ٢ | 8 | © | © | ٢ | ٢ |
| Terzi 2009 | ? | ٢ | 8 | © | © | ٢ | ٢ |
| Wang 2013 | ? | ٢ | ٢ | ٢ | © | ٢ | ٢ |
| Zhao 2018 | ? | ٢ | 8 | © | © | ٢ | ٢ |

Source Control Cont















| , | | | | | | | |
|---|--|---|--|---|---|---|---|
| | Ramett Liniw | ercal II | Hollada | 1 VI | | Odds Ratio | Orida Batio |
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Cooke 2016 | 39 | 41 | 36 | 41 | 7.6% | 1.54 [0.24, 9.73] | |
| Gokce 2017 | 82 | 86 | 84 | 86 | 16.0% | 0.49 [0.09, 2.74] | |
| Kane 2016 | 144 | 156 | 144 | 156 | 45.2% | 1.00 [0.43, 2.30] | - |
| Kane 2017 | 129 | 137 | 131 | 137 | 31.2% | 0.74 [0.25, 2.19] | |
| Total (95% CI) | | 420 | | 420 | 100.0% | 0.88 [0.49, 1.57] | • |
| Total events | 394 | | 397 | | 1990 (1990) - College (1990) - College | | 1 |
| Heterogeneity: Chi ² = 0 | 0.99, df = 3 (| P = 0.60) |); l ² = 0% | | | 1 | |
| Test for overall effect: | Z = 0.44 (P = | 0.66) | | | | | Favours Barrett Universal Favours Holladay 1 |
| E) | | | | | | | |
| -/ | Barrett Univ | ersal II | Hollada | w 2 | | Odds Ratio | Odds Ratio |
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Cooke 2016 | 39 | 41 | 37 | 41 | 7.4% | 2.11 [0.36, 12.20] | |
| Gokce 2017 | 82 | 66 | 83 | 86 | 15.6% | 0.74 [0.16, 3.41] | |
| Kane 2016 | 144 | 156 | 143 | 156 | 45.0% | 1.09 [0.46, 2.47] | |
| Shrivastava 2016 | 40 | 50 | 39 | 50 | 31.9% | 1.13 [0.43, 2.96] | |
| Total (95% CI) | | 333 | | 333 | 100.0% | 1.12 [0.65, 1.94] | • |
| Total events | 305 | | 302 | | | | T |
| Heterogeneity: Chi ² = 0 | 0.78, df = 3 (| P = 0.85) |); l ² = 0% | | | 1 | |
| Test for overall effect: | Z = 0.42 (P = | 0.66) | | | | | Favours Barrett Universal Favours Holladay 2 |
| F) | | | | | | | • |
| • / | Racratt Link | ware al. II | SP 4 | / T | | Odds Ratio | Odds Patio |
| Study or Subgroup | Events | Tota | l Events | Tota | l Weigh | M-H. Fixed. 95% C | M-H, Fixed, 95% CI |
| Cooke 2016 | 39 | 41 | 1 39 | 41 | 9.1 | 1.00 [0.13, 7.46 | 1 |
| Kane 2016 | 144 | 156 | 6 144 | 156 | 52.87 | 1.00 [0.43, 2.30 | i —≢— |
| Shrivastava 2018 | 40 | 50 | 0 40 | 50 | 38.17 | 1.00 [0.38, 2.66 | 1 — ≢— |
| | | 2.41 | - | 2.4- | | | |
| Total (95% CI) | 222 | 24/ | · | 24/ | 100.07 | 1.00 [0.55, 1.83 | · • |
| Heteropeosity Chi ² - | 0.00 df = 2 | /P = 1 0/ | 01- F - 0 | | | | |
| Test for overall effect: | Z = 0.00 (P) | = 1.00) | v), i = v. | ~ | | | |
| C) | | | | | | | PAVOURS BARRETT UNIVERSAL PAVOURS NKK/I |
| (g) | | | | | | | |
| •, | | | | | | | |
| <i>c,</i> | Haigi | ls | HIII-RI | BF | | Odds Ratio | Odds Ratio |
| Study or Subgroup | Haigi Events | is Total | Hili-Ri Events | BF Total | Weight | Odds Ratio M-H, Fixed, 95% | Odds Ratio CI M-H, Fixed, 95% CI |
| Study or Subgroup Gokce 2017 | Halgi Events 79 | s Total 86 | Hili-Ri Events 83 | BF Total 86 | Weight 44.1% | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 | Odds Ratio CI M-H, Fixed, 95% CI |
| Study or Subgroup Gokce 2017 Shrivastava 2018 | Haigi Events 79 39 | s Total 86 50 | Hili-Ri Events 63 39 | BF Total 86 50 | Weight 44.13 55.93 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 | Odds Ratio CI M-H, Fixed, 95% CI 63] 56] |
| Study or Subgroup Gokce 2017 Shrivastava 2018 | Haigi Events 79 39 | s Total 86 50 | Hili-Ri Events 83 39 | 8F <u>Total</u> 86 50 | Weight 44.17 55.97 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 | Odds Ratio CI M-H, Fixed, 95% CI 63] 56] |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) | Halgi <u>Events</u> 79 39 | ls <u>Total</u> 86 50 136 | Hill-Ri Events 83 39 | BF <u>Total</u> 86 50 136 | Weight 44.13 55.93 100.07 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 | Odds Ratio CI M-H, Fixed, 95% CI 63] 58] 59] |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events | Halgi <u>Events</u> 79 39 118 | is <u>Total </u> 86 50 136 | Hill-Ri Events 83 39 122 | BF <u>Total</u> 86 50 136 | Weight 44.13 55.93 100.03 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 | Odds Ratio CI M-H, Fixed, 95% CI 58] |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Chi ² | Haigi <u>Events</u> 79 39 118 = 1.10, df | is <u>Total</u> 86 50 136 = 1 (P = | Hili-Ri <u>Events</u> 83 39 122 • 0.29); | BF <u>Total</u> 86 50 136 ² = 93 | Weight 44.17 55.97 100.07 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 | Odds Ratio CI M-H, Fixed, 95% CI 58] 59] 0.01 0.1 1 10 100 |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe | Halgi 79 39 118 = 1.10, df ct: Z = 0.77 | is Total 66 50 136 = 1 (P = (P = 0.4 | Hili-Ri <u>Events</u> 83 39 122 • 0.29); 44) | BF <u>Total</u> 86 50 136 ² = 97 | Weight 44.13 55.97 100.07 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 | Odds Ratio CI M-H, Fixed, 95% CI 53] 59] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe H) | Halgi 79 39 116 = 1.10, df ct: Z = 0.77 | s Total 86 50 136 = 1 (P = (P = 0.4 | Hili-R <u>Events</u> 83 39 122 : 0.29); 44) | 8F <u>Total</u> 86 50 136 ² = 97 | Weight 44.13 55.93 100.03 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 | Odds Ratio CI M-H, Fixed, 95% CI 53] 59] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF |
| Study or Subgroup Gokce 2017 Shrivastava 2016 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe H) | Haigi <u>Events</u> 79 39 116 = 1.10, df ct: Z = 0.77 Haigi | is <u>Total</u> <u>66</u> 50 <u>136</u> <u>- 1 (P - </u> (P - 0 is | Hill-Ri <u>Events</u> 83 39 122 0.29); I 44) Hoffer | 8F <u>Total</u> 86 50 136 ² - 9X Q | Weight 44.17 55.97 100.07 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 Odds Ratio | Odds Ratio CI M-H, Fixed, 95% CI 53] 59] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF Odds Ratio |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe H) Study or Subgroup | Haigi <u> Events</u> 79 39 116 = 1.10, df ct: Z = 0.77 Haigi Events | is Total 66 50 136 = 1 (P = (P = 0 is Total | Hill-Ri Events 83 39 122 0.29); 1 44) Hoffer Events | 8F <u>Total</u> 86 50 136 ² = 97 Q Total | Weight 44.17 55.97 100.07 | Odds Ratio <u>M-H, Fixed, 95%</u> 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 Odds Ratio M-H, Fixed, 95% | Odds Ratio C(M-H, Fixed, 95% C) 53] 59] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF Odds Ratio C(M-H, Fixed, 95% C) |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe H) Study or Subgroup Cooke 2016 | Haigi <u>79</u> 39 116 = 1.10, df ct: Z = 0.77 Haigi <u>Events</u> 41 | is <u>Total</u> 66 50 136 = 1 (P = 0.4 (P = 0.4 is <u>Total</u> 41 | Hill-Ri Events 83 39 122 0.29); 1 44) Hoffer Events 37 | BF <u>Total</u> 86 50 136 ² = 97 Q Total 41 | Weight 44.17 55.97 100.07 (Weight 0.87 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 Odds Ratio M-H, Fixed, 95% 9.96 [0.52, 191.5 | Odds Ratio C(M-H, Fixed, 95% C) 53] 59] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF Odds Ratio C(M-H, Fixed, 95% C) 23] |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe H) Study or Subgroup Cooke 2016 Day 2012 | Haigi 79 39 116 = 1.10, df ct: Z = 0.77 Haigi Events 41 143 | is <u>Total</u> <u>66</u> <u>50</u> <u>136</u> <u>-1 (P = </u> (P = <u>0.4</u> <u>is</u> <u>Total</u> <u>163</u> | Hill-Ri Events 83 39 122 0.29); 1 44) Hoffer Events 37 142 | BF <u>Total</u> 86 50 136 ² = 97 Q <u>Total</u> 41 163 | Weight 44.17 55.97 100.07 (Weight 0.87 30.57 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 Odds Ratio M-H, Fixed, 95% 9.96 [0.52, 191.5 1.06 [0.55, 2.6 | Odds Ratio C(M-H, Fixed, 95% C) 53] 59] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF Odds Ratio C(M-H, Fixed, 95% C) 23] 04] |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe H) Study or Subgroup Cooke 2016 Day 2012 Eom 2014 | Haigi 79 39 116 = 1.10, df ct: Z = 0.77 Haigi Events 41 143 66 | s Total 66 50 136 = 1 (P = (P = 0.4 s Total 41 163 75 | Hill-Ri Events 83 39 122 0.29); 1 44) Hoffer Events 37 142 66 | BF <u>Total</u> 86 50 136 ² - 97 Q <u>Total</u> 163 75 | Weight 44.17 55.97 100.07 (Weight 0.87 30.57 13.87 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 Odds Ratio M-H, Fixed, 95% 9.96 [0.52, 191.5 1.06 [0.55, 2.6 1.00 [0.37, 2.6 | Odds Ratio C(M-H, Fixed, 95% C) 53] 59] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF Odds Ratio C(M-H, Fixed, 95% C) 23] 04] |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe H) Study or Subgroup Cooke 2016 Day 2012 Eom 2014 Gokce 2017 | Haigi 79 39 116 = 1.10, df ct: Z = 0.77 Haigi Events 41 143 66 79 | is <u>Total</u> <u>66</u> <u>50</u> <u>136</u> <u>-1 (P = 0.4</u> <u>163</u> <u>75</u> <u>86</u> | Hill-Ri Events 83 39 122 0.29); 1 44) Hoffer Events 37 142 66 84 | BF <u>Total</u> 86 50 136 ² - 9X Q <u>Total</u> 163 75 86 | Weight 44.17 55.97 100.07 (Weight 0.87 30.57 13.87 12.07 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 Odds Ratio M-H, Fixed, 95% 9.96 [0.52, 191.5 1.06 [0.55, 2.6 1.00 [0.37, 2.6 0.27 [0.05, 1.5] | Odds Ratio C(M-H, Fixed, 95% C) 53] 58] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF Odds Ratio C(M-H, Fixed, 95% C) 23] 04] 66] |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe H) Study or Subgroup Cooke 2016 Day 2012 Eom 2014 Gokce 2017 Kane 2016 | Haigi 79 39 116 = 1.10, df ct: Z = 0.77 Haigi Events 41 143 66 79 142 | is <u>Total</u> 66 50 136 = 1 (P = 0.4 (P = 0.4) s <u>Total</u> 163 75 86 156 | Hill-Ri Events 83 39 122 0.29); 44) Hoffer Events 37 142 66 84 142 | BF <u>Total</u> 86 50 136 r ² = 9X Q <u>Total</u> 163 75 86 156 | Weight 44.17 55.97 100.07 (Weight 0.87 30.57 13.87 12.07 22.37 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 Odds Ratio M-H, Fixed, 95% 9.96 [0.52, 191.5 1.06 [0.55, 2.6 1.00 [0.37, 2.6 0.27 [0.05, 1.5 1.00 [0.46, 2.5] | Odds Ratio C(M-H, Fixed, 95% C) 53] 58] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF Odds Ratio C(M-H, Fixed, 95% C) 23] 04] 66] 33] |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe H) Study or Subgroup Cooke 2016 Day 2012 Eom 2014 Gokce 2017 Kane 2016 Shrivastava 2018 | Haigi 79 39 116 = 1.10, df ct: Z = 0.77 Haigi Events 41 143 66 79 142 39 | is <u>Total</u> <u>66</u> <u>50</u> <u>136</u> <u>-1 (P = 0.4</u> <u>163</u> <u>75</u> <u>86</u> <u>156</u> <u>50</u> | Hill-Ri Events 83 39 122 0.29); 1 44) Hoffer Events 37 142 66 84 142 38 | BF Total 86 50 136 4 ² - 97 Q Total 163 75 86 156 50 | Weight 44.17 55.97 100.07 (Weight 0.87 30.57 13.87 12.07 22.37 14.67 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 Odds Ratio M-H, Fixed, 95% 9.96 [0.52, 191.5 1.06 [0.55, 2.6 1.00 [0.37, 2.6 0.27 [0.05, 1.5 1.00 [0.46, 2.5] 1.12 [0.44, 2.6] | Odds Ratio C(M-H, Fixed, 95% C) 53] 58] 59] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF Odds Ratio C(M-H, Fixed, 95% C) 23] 04] 66] 33] 4 |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe H) Study or Subgroup Cooke 2016 Day 2012 Eom 2014 Gokce 2017 Kane 2016 Shrivastava 2018 Srivannaboon 2013 | Haigi 79 39 116 = 1.10, df ct: Z = 0.77 Haigi Events 41 143 66 79 142 39 11 | s Total 66 50 136 = 1 (P = - (P = 0 (P = 0 (P = 0) 5 Total 41 163 75 86 156 50 15 | Hill-Ri Events 83 39 122 0.29); 1 44) Hoffer Events 37 142 66 84 142 38 13 | BF Total 86 50 136 4 ² - 97 Q Total 163 75 86 156 50 15 | Weight 44.17 55.97 100.07 (Weight 0.67 30.57 13.67 12.07 22.37 14.67 6.17 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 Odds Ratio M-H, Fixed, 95% 9.96 [0.52, 191.7 1.06 [0.55, 2.6 1.00 [0.37, 2.6 0.27 [0.05, 1.5 1.00 [0.46, 2.5 1.12 [0.44, 2.1 0.42 [0.06, 2.5] | Odds Ratio C(M-H, Fixed, 95% C) 53] 56] 59] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF Odds Ratio C(M-H, Fixed, 95% C) 23] 04] 66] 33] 77] |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe H) Study or Subgroup Cooke 2016 Day 2012 Eom 2014 Gokce 2017 Kane 2016 Shrivastava 2018 Srivannaboon 2013 Terzi 2009 | Haigi 79 39 116 = 1.10, df ct: Z = 0.77 Haigi Events 41 143 66 79 142 39 11 19 | s Total 66 50 136 = 1 (P = (P = 0.4 s Total 41 163 75 86 156 50 15 19 | Hill-Ri Events 83 39 122 0.29); 1 44) Hoffer Events 37 142 66 84 142 38 13 19 | BF Total 86 50 136 4 ² - 97 Q Total 41 163 75 86 156 50 15 19 | Weight 44.17 55.97 100.07 (Weight 0.87 30.57 13.87 12.07 22.37 14.67 6.17 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 0.74 [0.34, 1.5 0.74 [0.34, 1.5 1.06 [0.55, 2.6 1.06 [0.55, 2.6 1.00 [0.37, 2.6 0.27 [0.05, 1.5 1.00 [0.46, 2.5 1.12 [0.44, 2.1] 0.42 [0.06, 2.5 Not estima | Odds Ratio C(M-H, Fixed, 95% C) 53] 56] 59] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF Odds Ratio C(M-H, Fixed, 95% C) 23] 04] 66] 33] 77] bie |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe H) Study or Subgroup Cooke 2016 Day 2012 Eom 2014 Gokce 2017 Kane 2016 Shrivastava 2018 Srivannaboon 2013 Terzi 2009 | Haigi 79 39 116 = 1.10, df ct: Z = 0.77 Haigi Events 41 143 66 79 142 39 11 19 | s Total 66 50 136 = 1 (P = 0.4 (P = 0.4) s Total 163 75 86 156 50 15 19 | Hill-Ri Events 83 39 122 0.29); 1 44) Hoffer Events 37 142 66 84 142 38 13 19 | BF Total 86 50 136 4 ² - 97 Q Total 41 163 75 86 156 50 15 19 | Weight 44.17 55.97 100.07 (Weight 0.87 30.57 13.87 12.07 22.37 14.67 6.17 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 0.74 [0.34, 1.5 0.74 [0.34, 1.5 1.06 [0.55, 2.6 1.00 [0.37, 2.6 0.27 [0.05, 1.5 1.00 [0.46, 2.5 1.12 [0.44, 2.1] 0.42 [0.06, 2.5 Not estima | Odds Ratio C(M-H, Fixed, 95% C) 53] 58] 59] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF Odds Ratio C(M-H, Fixed, 95% C) 23] 04] 66] 33] 77] ble |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe H) Study or Subgroup Cooke 2016 Day 2012 Eom 2014 Gokce 2017 Kane 2016 Shrivastava 2018 Srivannaboon 2013 Terzi 2009 Total (95% CI) | Haigi 79 39 116 = 1.10, df ct: Z = 0.77 Haigi Events 41 143 66 79 142 39 11 19 | s Total 66 50 136 = 1 (P = 0.4 (P = 0.4) s Total 163 75 86 156 50 15 19 605 | Hill-Ri Events 83 39 122 0.29); 44) Hoffer Events 37 142 66 84 142 38 13 19 | BF Total 86 50 136 4 ² - 9X Q Total 41 163 75 86 156 50 15 19 605 | Weight 44.17 55.97 100.07 (Weight 0.87 30.57 13.87 12.07 22.37 14.67 6.17 100.07 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 0.74 [0.34, 1.5 0.74 [0.34, 1.5 1.06 [0.55, 2.0 1.06 [0.55, 2.0 1.00 [0.37, 2.6 0.27 [0.05, 1.5 1.00 [0.46, 2.5 1.12 [0.44, 2.1] 0.42 [0.06, 2.5 Not estima 0.98 [0.68, 1.4 | Odds Ratio C(M-H, Fixed, 95% C) 53] 58] 59] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF Odds Ratio C(M-H, Fixed, 95% C) 23] 04] 66] 33] 77] ble 42] |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe H) Study or Subgroup Cooke 2016 Day 2012 Eom 2014 Gokce 2017 Kane 2016 Shrivastava 2018 Srivannaboon 2013 Terzi 2009 Total (95% CI) Total events | Haigi 79 39 118 = 1.10, df ct: Z = 0.77 Haigi Events 41 143 66 79 142 39 11 19 540 | s Total 86 50 136 = 1 (P = 0.4 s Total 41 163 75 86 156 50 15 19 605 | Hill-Ri Events 83 39 122 0.29); 44) Hoffer Events 37 142 66 84 142 38 13 19 | BF Total 86 50 136 4 2 - 97 Q Total 41 163 75 86 156 50 15 19 605 | Weight 44.17 55.97 100.07 (Weight 0.87 30.57 13.87 12.07 22.37 14.67 6.17 100.07 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 Odds Ratio M-H, Fixed, 95% 9.96 [0.52, 191.3 1.06 [0.55, 2.0 1.00 [0.37, 2.6 0.27 [0.05, 1.3 1.00 [0.46, 2.3 1.12 [0.44, 2.1] 0.42 [0.06, 2.3 Not estima 0.98 [0.68, 1.4 | Odds Ratio C(M-H, Fixed, 95% C) 53] 58] 59] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF Odds Ratio C(M-H, Fixed, 95% C) 23] 04] 66] 33] 77] ble 42] |
| Study or Subgroup Gokce 2017 Shrivastava 2018 Total (95% CI) Total events Heterogeneity: Ch ² Test for overall effe H) Study or Subgroup Cooke 2016 Day 2012 Eom 2014 Gokce 2017 Kane 2016 Shrivastava 2018 Srivannaboon 2013 Terzi 2009 Total (95% CI) Total events Heterogeneity: Ch ² | Haigi 79 39 118 = 1.10, df ct: Z = 0.77 Haigi Events 41 143 66 79 142 39 11 19 540 = 5.78, df | s Total 86 50 136 - 1 (P = 0.4 s Total 41 163 75 86 156 50 15 19 605 = 6 (P = - | Hill-Ri Events 83 39 122 0.29); 44) Hoffer Events 37 142 66 64 142 36 13 19 541 | BF Total 86 50 136 4 ² = 9X Q Total 41 163 75 86 156 50 15 19 605 ² = 0X | Weight 44.17 55.97 100.07 (Weight 0.87 30.57 13.87 12.07 22.37 14.67 6.17 14.67 6.17 | Odds Ratio M-H, Fixed, 95% 0.41 [0.10, 1.6 1.00 [0.39, 2.5 0.74 [0.34, 1.5 Odds Ratio M-H, Fixed, 95% 9.96 [0.52, 191.3 1.06 [0.55, 2.0 1.00 [0.37, 2.6 0.27 [0.05, 1.3 1.00 [0.46, 2.3 1.12 [0.44, 2.1] 0.42 [0.06, 2.3 Not estima 0.98 [0.68, 1.4 | Odds Ratio C(M-H, Fixed, 95% C) 53] 58] 59] 0.01 0.1 1 10 100 Favours Haigis Favours Hill-RBF Odds Ratio C(M-H, Fixed, 95% C) 23] 04] 66] 33] 77] ble 42] 0.01 0.1 1 10 100 |

| 1) | | | | | | | |
|--|------------------------|--------------------|-------------------|---------------------|---------|---------------------|---|
| | Halo | s | Hollada | av1 | | Odds Ratio | Odds Ratio |
| Study or Subaroup | Events | Total | Events | Total | Weight | M-H. Fixed. 95% CI | M-H. Fixed, 95% CI |
| Cooke 2016 | 41 | 41 | 38 | 41 | 1.2% | 7 55 10 38 150 871 | |
| Day 2012 | 143 | 163 | 140 | 163 | 45 9% | 1 17 10 62 2 231 | _ |
| Gokce 2017 | 79 | RG | R4 | 86 | 18 34 | 0 27 10 05 1 331 | e |
| Kape 2016 | 142 | 156 | 144 | 156 | 34 64 | 0.85 10 38 1 891 | |
| | 175 | | 144 | 1.04 | 0-1-0/A | 0.05 [0.50] 1.05] | |
| Total (95% CI) | | 446 | | 446 | 100.0% | 0.97 [0.62, 1.54] | |
| Total events | 405 | | 406 | | | | Ť |
| | 4.72 df | = 3 (P | = 0.19) | r = 36 | ¥. | | |
| Test for overall effect: | Z = 0.12 | $(\mathbf{P} = 0)$ | .91) | | | | 0.01 0.1 1 10 100 |
| | | ų. – v | | | | | Favours Haigis Favours Holladay 1 |
| J) | | | | | | | |
| | Halgi | 5 | Hollada | ay 2 | | Odds Ratio | Odds Ratio |
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Cooke 2016 | 41 | 41 | 37 | 41 | 1.4% | 9.96 [0.52, 191.23] | · · · · · · · · · · · · · · · · · · · |
| Gokce 2017 | 79 | 66 | 63 | 86 | 21.4% | 0.41 [0.10, 1.63] | _ |
| Kane 2016 | 142 | 156 | 143 | 156 | 40.7% | 0.92 [0.42, 2.03] | _ |
| Shrivastava 2018 | 40 | 50 | 39 | 50 | 24.7% | 1.13 (0.43, 2.96) | _ |
| Srivannaboon 2013 | 11 | 15 | 14 | 15 | 11.6% | 0.20 [0.02, 2.02] | _ |
| Terzi 2009 | 19 | 19 | 19 | 19 | | Not estimable | |
| · •·· - • • • | | | | | | | |
| Total (95% CI) | | 367 | | 367 | 100.0% | 0.90 [0.55, 1.50] | + |
| Total events | 332 | | 335 | | | | |
| Heterogeneity: Chi ² = | 5.65, df | = 4 (P · | = 0.23); | r ² = 29 | × | | |
| Test for overall effect: | Z = 0.39 | (P = 0) | .70) | | | | 0.01 0.1 1 10 100 |
| 14) | | • | | | | | ravours naigis ravours noiladay z |
| К) | | | | | | | |
| | Haig | İs | \$RK | /т | | Odds Ratio | Odds Ratio |
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% C | I M-H, Fixed, 95% CI |
| Cooke 2016 | 41 | 41 | 39 | 41 | 1.2% | 5.25 [0.24, 112.88 |] |
| Day 2012 | 143 | 163 | 137 | 163 | 43.1% | 1.36 [0.72, 2.54 | j _∔∎ |
| Kane 2016 | 142 | 156 | 144 | 156 | 33.1% | 0.85 [0.38, 1.89 | j — - |
| Shrivastava 2018 | 39 | 50 | 40 | 50 | 22.6% | 0.89 [0.34, 2.32 | j |
| Terzi 2009 | 19 | 19 | 19 | 19 | | Not estimable | |
| | | | | | | | - |
| Total (95% CI) | | 429 | | 429 | 100.0% | 1.13 [0.73, 1.74 | 1 🔶 |
| Total events | 364 | | 379 | | | | |
| Heterogeneity: Chi ² = | 2.03, df | = 3 (P | = 0.57); | $l^2 = 0$ | × | | |
| Test for overall effect: | Z = 0.55 | i (P = (| 0.58) | | | | U.UI U.I I IU IUU Fouquer Mainir Fouquer SPE/T |
| 1. | | - | | | | | ravouis naigis ravouis SKK/ I |
| L) | | | | | | | |
| | Hill-R | BF | Hoffe | r Q | | Odds Ratio | Odds Ratio |
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Gokce 2017 | 63 | 86 | 64 | 86 | 26.0% | 0.66 [0.11, 4.04] | |
| Shrivastava 2018 | 39 | 50 | 38 | 50 | 74.0% | 1.12 [0.44, 2.84] | |
| | | | | | | | T |
| Total (95% CI) | | 136 | | 136 | 100.0% | 1.00 [0.44, 2.28] | |
| Total events | 122 | | 122 | | | | |
| Heterogeneity: Chi ² = 1 | 0.26, df | = 1 (P | = 0.61); | r ² = 07 | í | | |
| Test for overall effect: | Z = 0.00 | (P = 1 | .00) | | | | Favours Hill-RRF Favours Hoffer () |
| NA) | | | | | | | |
| 111) | | | | - | | A.L! | A 11 - 1 |
| • • • • • • | HIII-RI | SF . | Hollada | y 1 | | Odds Ratio | Odds Ratio |
| study or Subgroup | Events | Total | events | Total | weight | M-H, FIXED, 95% CI | M-H, Fixed, 95% Cl |
| Gokce 2017 | 83 | 66 | 64 | 66 | 33.8% | 0.66 [0.11, 4.04] | - |
| Kane 2017 | 131 | 137 | 131 | 137 | 66.2X | 1.00 (0.31, 3.16) | |
| | | | | *** | 100.00 | 0.00 0.00 0.00 | |
| 10tal (95% CI) | * | 223 | | 223 | 100.0% | 0.66 [0.33, 2.34] | |
| i otal events | 214 | | 215 | 2 | | | |
| Traction and the second | V.14,01 • 7 - ^ ^ - | - 1 (P | = 0.70); i eas | - = 0% | | | 0.01 0.1 1 10 100 |
| rest for overall effect: | z = 0.25 | (r = Q. | .00) | | | | Favours Hill-RBF Favours Holladay 1 |

| N) | | | | | | | | |
|-------------------------------------|---------------|---------------|-----------------|-------------------|-----------------|--------------------------------------|----------|--|
| | Hill-R | BF | Hollada | iy 2 | | Odds Ratio | | Odds Ratio |
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | | M-H, Fixed, 95% CI |
| Gokce 2017 | 63 | 66 | 63 | 86 | 25.2% | 1.00 [0.20, 5.10] | | <u> </u> |
| Shrivastava 2016 | 39 | 50 | 39 | 50 | 74.6% | 1.00 [0.39, 2.58] | | |
| Total (95% CI) | | 136 | | 136 | 100.0% | 1 00 10 44 2 27 | 1 | |
| Total events | 122 | 1.04 | 122 | 2.54 | 100.075 | 1.00 [0.14, 227] | | |
| Heterogeneity: Chi ² = | 0.00. df | = 1 (P) | = 1.00); (| ² = 0% | | | b | |
| Test for overall effect: | Z = 0.00 | (P = 1 | .00) | • • • • | | | 0.01 | |
| 0) | | • | | | | | | ravours nill-ker ravours nolladay 2 |
| 0) | | | | | | | | |
| A | Hoffer | Q | Hollada | y 1 | MI-1-L- | Odds Ratio | | Odds Ratio |
| Study or Subgroup | Events | TOTAL | Events | TOTAL | weight | M-H, FIXED, 9576 CI | | M-H, FIXED, 95% CI |
| Aristodemou 2011 | 539 | 606 | 542 | 606 | 62.7% 3 PM | 0.95 [0.67, 1.36] | | |
| COOKE 2010 | 142 | 163 | 30 140 | 163 | 3.07 18 AV | 0.75 [0.15, 5.49] | | |
| Cokre 2017 | 142 R4 | 86 | R4 | 86 | 2.0% | | | |
| Kane 2016 | 142 | 156 | 144 | 156 | 13.2% | 0.85 [0.38, 1.89] | | _ |
| | | | | | | | | |
| Total (95% CI) | | 1054 | | 1054 | 100.0% | 0.96 [0.72, 1.27] | | + |
| Total events | 944 | | 946 | _ | | | | |
| Heterogeneity: Chi ² = | 0.42, df • | = 4 (P · | = 0.98); I | ² = 0% | | | 0.01 | 0,1 1 10 100 |
| Test for overall effect: | Z = 0.29 | (P = 0 | .77) | | | | V.VI | Favours Hoffer Q Favours Holladay 1 |
| P) | | | | | | | | |
| •) | Hoffer | 0 | Hollada | v 2 | | Odds Ratio | | Odds Ratio |
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | | M-H, Fixed, 95% CI |
| Cooke 2016 | 37 | 41 | 37 | 41 | 12.2% | 1.00 [0.23, 4.30] | | |
| Gokce 2017 | 64 | 86 | 83 | 86 | 6.5% | 1.52 [0.25, 9.32] | | - |
| Kane 2016 | 142 | 156 | 143 | 156 | 43.4% | 0.92 [0.42, 2.03] | | # |
| Shrivastava 2018 | 38 | 50 | 39 | 50 | 31. 6% | 0.89 [0.35, 2.27] | | |
| Srivannaboon 2013 | 13 | 15 | 14 | 15 | 6.3X | 0.46 [0.04, 5.75] | | |
| Terzi 2009 | 19 | 19 | 19 | 19 | | Not estimable | | |
| Total (95% CI) | | 367 | | 367 | 100.0% | 0 93 10 56 1 571 | | |
| Total events | 333 | *** | 335 | *** | | | | Ť |
| Heterogeneity: $Chi^2 = 1$ | 0.59. df • | = 4 (P · | = 0.96): 1 | ² = 0% | | | L | |
| Test for overall effect: | Z = 0.26 | (P = 0) | .79) | | | | 0.01 | 0.1 1 10 100 Favour: Hoffer () Favour: Holladay 2 |
| \circ | | | | | | | | Tarours noner & Tarours noneday E |
| Q) | | - | **** | | | | | |
| e | Hoffe | er Q Tanal | SRK | /T | NU-1-L- | Odds Ratio | <i></i> | Odds Ratio |
| Study or Subgroup | Events | COR | Events | LOTA | neign | t M-n, Fixed, 9976 | <u>L</u> | M-R, Fixed, 99% CI |
| Aristopemou 2011 Cooka 2016 | 37 | 41 | 30 | 41 | 2.07 2.45 | 1.17 [V.02, 1.0 6 0.47 [0.08 2.7 | 10] | |
| COOKE 2010 | 142 | 141 | . 39 | 163 | . 3.47 16 84 | 0.47 [0.00, 2.7 (1.28 [0.20, 2.3 | 01 01 | |
| Casto 2007 | 26 | 41 | 22 | 41 | 15.07 7.29 | 1.20 [0.05, 2.3 | 21 21 | |
| Kane 2016 | 142 | 156 | 144 144 | 156 | 11.59 | 6 0.85 IO.38 1 8 | :91 | _ |
| Shrivastava 2018 | 38 | 50 | 40 | 50 | 8.61 | 0.79 10.31 2.0 | 51 | _ |
| Terzi 2009 | 19 | 19 | 19 | 19 | | Not estimat | ile | |
| | - | - | - | - | | | | |
| Total (95% CI) | | 1078 | l . | 1075 | 100.05 | 6 1.12 [0.86, 1.4 | 4] | ♠ |
| Total events | 943 | | 930 | | - | | | |
| Heterogeneity: Chi ² = | 2.55, df | = 5 (P | = 0.77); | ; | × | | 0.01 | 0,1 1 10 100 |
| lest for overall effect | z = 0.64 | 4 (P = | 0.40} | | | | | Favours Hoffer Q Favours SRK/T |
| R) | | | | | | | | - |
| * | Hollada | y 1 | Holladay | 2 | | Odds Ratio | | Odds Ratio |
| Study or Subgroup | Events | Total | Events | Total 1 | Weight I | M-H, Fixed, 95% CI | | M-H, Fixed, 95% CI |
| Cooke 2016 | 38 | 41 | 37 | 41 | 17.3% | 1.37 [0.29, 6.54] | | |
| Gokce 2017 | 84 | 86 | 83 | 86 | 12.3% | 1.52 [0.25, 9.32] | | _ = |
| Kane 2016 | 144 | 156 | 143 | 156 | 70.3% | 1.09 [0.48, 2.47] | | |
| Total (95% CP) | | 722 | | 782 . | 100.01 | 1 10 /061 3 221 | | |
| Total (73/8 CI) | 266 | 243 | 262 | 20) / | | 1.17 [0.01, 2.33] | | |
| Heterocenetive Chi ² – 4 | 200 14 df- | 2 (P - | 203 1.931- P | | | | | |
| Test for overall effect: | Z = 0.51 | (P = 0 | 61) | - 1/4 | | | 0.01 | 0.1 1 10 100 |
| | | ·· - •. | ÷-) | | | | Fa | avours Holladay 1 Favours Holladay 2 |

| S) | | | | | | | |
|---|--|---|---|---|---|---|----------------------------------|
| | Hollada | ay 1 | \$RK/ | т | | Odds Ratio | Odds Ratio |
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Aristodemou 2011 | 542 | 608 | 529 | 608 | 63.3% | 1.23 [0.87, 1.74] | |
| Cooke 2016 | 36 | 41 | 39 | 41 | 3.1% | 0.65 [0.10, 4.11] | |
| Day 2012 | 140 | 163 | 137 | 163 | 21.3% | 1.16 [0.63, 2.12] | - |
| Kane 2016 | 144 | 15 6 | 144 | 156 | 12.2% | 1.00 [0.43, 2.30] | |
| Total (95% CI) | | 968 | | 968 | 100.0% | 1.17 [0.88, 1.54] | • |
| Total events | 864 | | 649 | | | | |
| Heterogeneity: Chi ² = | 0.60, df | = 3 (P · | = 0.90); | i² = 0% | | | |
| Test for overall effect: | Z = 1.07 | ' (P = 0 | .28) | | | | Favours Holladay 1 Favours SRK/T |
| Т) | | | | | | | |
| | | | | | | | |
| | Hollad | ay 2 | \$RK | /т | | Odds Ratio | Odds Ratio |
| Study or Subgroup | Hollad Events | ay 2 Total | ŞRK, Events | /T Total | Weight | Odds Ratio M-H, Fixed, 95% CI | Odds Ratio M-H, Fixed, 95% Ci |
| Study or Subgroup | Hollad Events 37 | ay 2 Total 41 | SRK, Events 39 | /T Total 41 | Weight 15.5% | Odds Ratio M-H, Fixed, 95% CI 0.47 [0.08, 2.75] | Odds Ratio M-H, Fixed, 95% CI |
| Study or Subgroup Cooke 2016 Kane 2016 | Hollad Events 37 143 | ay 2 Total 41 156 | SRK, Events 39 144 | /T Total 41 156 | Weight 15.5% 48.8% | Odds Ratio M-H, Fixed, 95% CI 0.47 [0.06, 2.75] 0.92 [0.40, 2.08] | Odds Ratio M-H, Fixed, 95% Cl |
| Study or Subgroup Cooke 2016 Kane 2016 Shrivastava 2018 | Hollad Events 37 143 39 | ay 2 Total 41 156 50 | \$RK, Events 39 144 40 | /T Total 41 156 50 | Weight 15.5% 48.8% 35.8% | Odds Ratio M-H, Fixed, 95% CI 0.47 [0.08, 2.75] 0.92 [0.40, 2.08] 0.89 [0.34, 2.32] | Odds Ratio M-H, Fixed, 95% CI |
| Study or Subgroup Cooke 2016 Kane 2016 Shrivastava 2018 Terzi 2009 | Hollad Events 37 143 39 19 | ay 2 Total 41 156 50 19 | SRK, Events 39 144 40 19 | /T Total 41 156 50 19 | Weight 15.5% 48.8% 35.8% | Odds Ratio M-H, Fixed, 95% C1 0.47 [0.08, 2.75] 0.92 [0.40, 2.08] 0.89 [0.34, 2.32] Not estimable | Odds Ratio M-H, Fixed, 95% Ci |
| Study or Subgroup Cooke 2016 Kane 2016 Shrivastava 2018 Terzi 2009 Total (95% CI) | Hollad Events 37 143 39 19 | ay 2 Total 41 156 50 19 266 | SRK, Events 39 144 40 19 | /T Total 41 156 50 19 266 | Weight 15.5% 48.8% 35.8% | Odds Ratio M-H, Fixed, 95% CI 0.47 [0.06, 2.75] 0.92 [0.40, 2.06] 0.89 [0.34, 2.32] Not estimable 0.84 [0.47, 1.50] | Odds Ratio M-H, Fixed, 95% Ci |
| Study or Subgroup Cooke 2016 Kane 2016 Shrivastava 2018 Terzi 2009 Total (95% CI) Total events | Hollad Events 37 143 39 19 236 | ay 2 Total 41 156 50 19 266 | \$RK, <u>Events</u> 39 144 40 19 242 | /T Total 41 156 50 19 266 | Weight 15.5% 48.8% 35.8% 100.0% | Odds Ratio M-H, Fixed, 95% CI 0.47 [0.08, 2.75] 0.92 [0.40, 2.08] 0.89 [0.34, 2.32] Not estimable 0.84 [0.47, 1.50] | Odds Ratio M-H, Fixed, 95% CI |
| Study or Subgroup Cooke 2016 Kane 2016 Shrivastava 2018 Terzi 2009 Total (95% Cl) Total events Heterogeneity: Chi ² = | Hollad Events 37 143 39 19 236 0.46, df | ay 2 <u>Total</u> 41 156 50 19 266 = 2 (P | \$RK, <u>Events</u> 39 144 40 19 242 = 0.79); | /T <u>Total</u> 41 156 50 19 266 F = 07 | Weight 15.5% 48.8% 35.8% 100.0% | Odds Ratio M-H, Fixed, 95% CI 0.47 [0.08, 2.75] 0.92 [0.40, 2.08] 0.89 [0.34, 2.32] Not estimable 0.84 [0.47, 1.50] | Odds Ratio M-H, Fixed, 95% CI |
| Study or Subgroup Cooke 2016 Kane 2016 Shrivastava 2018 Terzi 2009 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: | Hollad Events 37 143 39 19 238 0.46, df Z = 0.55 | ay 2 Total 41 156 50 19 266 = 2 (P) (P = 0 | \$RK, <u>Events</u> 39 144 40 19 242 = 0.79); 55) | /T <u>Total</u> 41 156 50 19 266 I ² = 07 | Weight 15.5% 48.8% 35.8% 100.0% | Odds Ratio M-H, Fixed, 95% CI 0.47 [0.08, 2.75] 0.92 [0.40, 2.08] 0.89 [0.34, 2.32] Not estimable 0.84 [0.47, 1.50] | Odds Ratio M-H, Fixed, 95% CI |



Funnel plot using data of 11 studies comparing Mean absolute error between Haigis and Hoffer Q

